Synapse - Dean Bajorin

Results (663)

Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC)

Meeting Abstract

Iyer, G.; Balar, A. V.; Milowsky, M. I.; Huang, W. C.; Woods, M.; Donat, S. M.; Herr, H. W.; Dalbagni, G.; Bochner, B. H.; Ostrovnaya, I.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab

Meeting Abstract

Funt, S.; Charen, A. S.; Yusko, E.; Vignali, M.; Benzeno, S.; Boyd, M. E.; Moran, M. M.; Kania, B. E.; Cipolla, C. K.; Regazzi, A. M.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts)

Meeting Abstract

Bajorin, D. F.; Sharma, P.; Quinn, D. I.; Plimack, E. R.; Hoffman-Censits, J. H.; O'Donnell, P. H.; Siefker-Radtke, A. O.; Sheikh, N. A.; Lill, J. S.; Trager, J. B.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

KEYNOTE-057: Phase II study of pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)

Meeting Abstract

Kamat, A. M.; Bellmunt, J.; Choueiri, T. K.; Nam, K.; De Santis, M.; Dreicer, R.; Hahn, N. M.; Perini, R.; Siefker-Radtke, A.; Sonpavde, G.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

Keynote-045: Open-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer

Meeting Abstract

Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
Journal for ImmunoTherapy of Cancer (2016)

Fulltext@MSK | Save

Phase I study of everolimus in combination with gemcitabine and split-dose cisplatin in advanced urothelial carcinoma

Journal Article

Abida, W.; Milowsky, M. I.; Ostrovnaya, I.; Gerst, S. R.; Rosenberg, J. E.; Voss, M. H.; Apolo, A. B.; Regazzi, A. M.; McCoy, A. S.; Boyd, M. E.; more...
Bladder Cancer (2016)

Fulltext@MSK | Save

Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study

Meeting Abstract

de Wit, R.; Kamat, A. M.; Bellmunt, J.; Choueiri, T. K.; Nam, K.; De Santis, M.; Dreicer, R.; Hahn, N. M.; Perini, R.; Siefker-Radtke, A. O.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study

Meeting Abstract

Balar, A.; Bellmunt, J.; O'Donnell, P. H.; Castellano, D.; Grivas, P.; Vuky, J.; Powles, T.; Plimack, E. R.; Hahn, N. M.; de Wit, R.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Clinical evaluation of cisplatin sensitivity of germline polymorphisms in neoadjuvant chemotherapy for urothelial cancer

Journal Article

O'Donnell, P. H.; Alanee, S.; Stratton, K. L.; Garcia-Grossman, I. R.; Cao, H.; Ostrovnaya, I.; Plimack, E. R.; Manschreck, C.; Ganshert, C.; Smith, N. D.; more...
Clinical Genitourinary Cancer (2016)

Fulltext@MSK | Save

Genomic characterization of response to chemoradiation in urothelial bladder cancer

Journal Article

Desai, N. B.; Scott, S. N.; Zabor, E. C.; Cha, E. K.; Hreiki, J.; Sfakianos, J. P.; Ramirez, R.; Bagrodia, A.; Rosenberg, J. E.; Bajorin, D. F.; more...
Cancer (2016)

Fulltext@MSK | Save